Clinical trials: Glioblastoma, IDH-wildtype
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
WP1066 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This phase II trial tests how well the combination of WP1066 and radiation therapy works in treating newly diagnosed glioblastoma.
- Trial name
- NCT05879250
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Northwestern University
Relapsed Cancer, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol).
- Trial name
- GBrecurr (NCT06430424)
- Testing
- Relapsed glioblastoma
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Bordeaux
Glioblastoma, IDH-wildtype, MGMT-Methylated Glioblastoma
Regorafenib With Temozolomide With or Without RT in MGMT-Methylated, IDH Wild-type GBM Patients
This study will evaluate the addition of regorafenib to standard of care treatment with TMZ as adjuvant therapy, and in combination with TMZ+RT as concomitant therapy.
- Trial name
- REGOMA-2 (NCT06095375)
- Testing
- Regorafenib, Temozolomide
- Where
- 2 sites in Italy
- Volunteers
- 21 people
- Sponsor
- Istituto Oncologico Veneto IRCCS
Glioma, Glioma (Diagnosis)
GliomaAI-GBM: MRI-Based Detection of IDH Wildtype Glioblastoma
The goal of this observational study is to learn whether an artificial intelligence system called GliomaAI-GBM can help detect a specific molecular type of brain tumour called IDH wildtype glioblastoma using routine MRI scans.
- Conditions
- Glioma, Glioma (Diagnosis), Glioblastom WHO Grade 4, IDH Wildtype Glioblastoma
- Trial name
- GliomaAI-GBM (NCT07673692)
- Testing
- GliomaAI-GBM
- Where
- India
- Volunteers
- 1,372 people
- Sponsor
- Deep Learning Institute of Radiological Sciences
Glioblastoma
Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma
Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted…
- Trial name
- PRIDE (NCT05871021)
- Testing
- Dose escalation of radiation dose beyond the therapeutic standard
- Where
- 9 sites in Germany
- Volunteers
- 107 people
- Sponsor
- University Hospital Tuebingen
Grade III Astrocytoma, Grade IV Astrocytoma
Tadalafil to Overcome Immunosuppression During Chemoradiotherapy for IDH-wildtype Grade III-IV Astrocytoma
Increasing preclinical and clinical data have shown that myeloid-derived suppressor cells (MDSCs) may represent a significant driver of immunosuppression in glioblastoma (GBM, grade IV astrocytoma) and a potential mechanism of…
- Conditions
- Grade III Astrocytoma, Grade IV Astrocytoma, Astrocytoma, Grade IV, Astrocytoma, Grade III
- Trial name
- NCT04757662
- Testing
- Tadalafil
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
The primary objective of this study is to evaluate the dosimetry, safety, and tolerability of the investigational radiopharmaceutical [177Lu]Lu-XT771 in patients with recurrent glioblastoma, an aggressive form of brain cancer.
- Conditions
- Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma, Glioblastoma (GBM), Recurrent Glioblastoma IDH Wildtype
- Trial name
- NCT07648823
- Testing
- [177Lu]Lu-XT771
- Where
- 2 sites in China
- Volunteers
- 5 people
- Sponsor
- Beijing Tiantan Hospital
Glioblastoma
Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma
This study is being done to see if adding nivolumab to radiation therapy and bevacizumab can increase the effectiveness of the treatment for recurrent glioblastoma.
- Trial name
- NCT03743662
- Testing
- Re-irradiation (RT), Bevacizumab, Nivolumab
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma
A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma
This is a Phase 1, single-arm MT-125 dose escalation study followed by a Phase 2, randomized parallel design dose expansion phase, to determine the safety and tolerability of MT-125 administered 5 consecutive days a week with 2…
- Trial name
- NOVA-GBM (NCT07604285)
- Testing
- MT-125
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Myosin Therapeutics Inc.
Glioblastoma, Mismatch Repair Deficiency
Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency
Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma with Mismatch Repair Deficiency.
- Trial name
- NCT07385846
- Testing
- Pembrolizumab, Navifus Focused Ultrasound Sonification
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jennifer Leddon
Glioblastoma, Glioblastoma Multiforme
The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival.
- Conditions
- Glioblastoma, Glioblastoma Multiforme, Glioblastoma, IDH-wildtype, Glioblastoma Multiforme of Brain
- Trial name
- RECSUR (NCT06283927)
- Testing
- Re-resection, Temozolomide, Lomustine
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 464 people
- Sponsor
- Jasper Gerritsen
Primary Glioblastoma
Carbon Ion Radiotherapy for Primary Glioblastoma
Treatment standard for patients with primary glioblastoma (GBM) is combined radiochemotherapy with temozolomide (TMZ). Radiation is delivered up to a total dose of 60 Gy using photons.
- Trial name
- CLEOPATRA (NCT01165671)
- Testing
- Carbon Ion Radiotherapy, Proton Radiotherapy
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- University Hospital Heidelberg
Glioblastoma
Physiological MRI for Precision Radiotherapy IDH-wildtype Glioblastoma
After surgery, a key step in treatment of patients diagnosed with glioblastoma (high grade brain tumour) is radiotherapy. The ideal clinical target volume (CTV) for radiotherapy treatment planning includes all tumour cells…
- Trial name
- PhysMRRT (NCT05970757)
- Testing
- Extended MRI
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Erasmus Medical Center
Glioblastoma, IDH-wildtype
Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
Tailored approaches targeting crucial oncogenes and pathways have shown successful results in a number of cancer types and offer exciting perspective in neuro-oncology.
- Trial name
- OPTIMUM (NCT04945148)
- Testing
- Metformin, Radiation IMRT, Temozolomide
- Where
- 7 sites in France, Italy
- Volunteers
- 640 people
- Sponsor
- Hopital Foch
Glioblastoma, Malignant Glioma
Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics
The purpose of this study is to determine whether Q cells separated from the glioma sample are determinants in treatment response and prognosis of glioma patients
- Trial name
- NCT02047058
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Recurrent Glioblastoma, IDH-Wildtype, Recurrent MGMT-Methylated Glioblastoma
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy versus the usual chemotherapy…
- Trial name
- NCT05432804
- Testing
- Biospecimen Collection, Magnetic Resonance Imaging, Selinexor
- Where
- 39 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent).
- Conditions
- High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
- Trial name
- NCT05465954
- Testing
- Biospecimen Collection, Efineptakin alfa, Pembrolizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Mayo Clinic
IDH Family Wildtype, Recurrent Anaplastic Astrocytoma
Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
This phase II trial studies how well laser interstitial thermal therapy and lomustine work in treating patients with glioblastoma or anaplastic astrocytoma that has come back.
- Conditions
- IDH Family Wildtype, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma
- Trial name
- NCT03022578
- Testing
- Laser Interstitial Thermal Therapy, Lomustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Glioblastoma
Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)
The aim of this study is to investigate the (cost-)effectiveness of LITT (Laser Interstitial Thermal Therapy) in primary irresectable glioblastoma.
- Trial name
- EMITT (NCT05318612)
- Testing
- Laser Interstitial Thermal Therapy (LITT), Biopsy
- Where
- 7 sites in Netherlands
- Volunteers
- 238 people
- Sponsor
- Radboud University Medical Center
Glioblastoma
Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)
This is a multi-institutional, consortium-based, non-interventional prospective blinded endpoints clinical study to determine whether high activity of Cytochrome C Oxidase (CcO) in tumor specimens from subjects with newly…
- Trial name
- NCT02997423
- Where
- 19 sites in United States
- Volunteers
- 153 people
- Sponsor
- University of Iowa